KinoPharma
Antiviral Company
Developing safe topical treatment for cervical intraepithelial neoplasia (CIN),
human papillomavirus (HPV) infection of the cervix that could potentially lead to cervical cancer.
- All
- Press Release
- Announcement
2025/11/04Announcement
We hereby announce that the collaboration with Data4cs Inc.* (Headquarters: Minato-ku, Tokyo) regarding in silico analysis and evaluation, conducted as part of profiling studies for our kinase inhibitor program, was reported as a “Collaborative case study with Bio Venture” within the company’s pitch at the recently held Bio Japan/Health TECH JAPAN (October 8, 2025). We will continue to advance drug discovery research utilizing cutting edge technologies such as in silico analysis and AI, striving to deliver superior pharmaceuticals to patients suffering from disease as quickly as possible through multifaceted enhancement."
*Data4cs Inc.: A consulting and AI solutions company that supports problem-solving and business growth across diverse industries through data science. Founded in 2005 with marketing analytics services, it now operates in multiple sectors including finance and life sciences. Key services include data analysis, AI system development, and DX (Digital Transformation) support. The company also focuses on training data scientists both internally and externally.
2025/08/08Announcement
We are pleased to announce the summary results of a Phase 2 clinical study of our ointment drug for the indication of verruca vulgaris being developed in collaboration with Iwaki Seiyaku CO.,LTD.
About Summary Results of Phase 2 Clinical Study on Verruca Vulgaris conducted by KinoPharma in collaboration with Iwaki Seiyaku as a Japanese Partner2025/07/22Announcement
KinoPharma is pleased to announce that as for our novel antiviral drug, we were allowed to grant the use patent for BPV infection by European Patent Office(EPO)
Patent Approved for Novel Antiviral Drug for Bovine Papillomavirus Infection in Europe2023/04/07Press Release
Phase 2 clinical trial initiated for the treatment of cutaneous warts, a human papillomavirus infection.
- Development of a novel antiviral drug against human papillomavirus -
2020/07/06Press Release
Kinopharma is delighted to announce the registration of the first subject in phase 1/2 clinical studies in Korea evaluating the safety and efficacy of the anti-HPV agent, Kinopharma’s flagship program, in patients with cervical intraepithelial neoplasia (CIN).
Cervical intraepithelial neoplasia (CIN) is human papillomavirus (HPV) infection of the cervix that could potentially lead to cervical cancer. Currently, there are no approved antiviral drugs for the treatment of CIN. Our clinical candidate anti-HPV agent is intended to treat CIN by removing any types of HPV from the cervix. We aim for the fastest approval of the anti-HPV agent.
2020/01/14Press Release
ASKA Pharmaceutical and KinoPharma Entered into Option Agreement for Treatment of Cervical Dysplasia.
View the press release (PDF)2025/11/04Announcement
We hereby announce that the collaboration with Data4cs Inc.* (Headquarters: Minato-ku, Tokyo) regarding in silico analysis and evaluation, conducted as part of profiling studies for our kinase inhibitor program, was reported as a “Collaborative case study with Bio Venture” within the company’s pitch at the recently held Bio Japan/Health TECH JAPAN (October 8, 2025). We will continue to advance drug discovery research utilizing cutting edge technologies such as in silico analysis and AI, striving to deliver superior pharmaceuticals to patients suffering from disease as quickly as possible through multifaceted enhancement."
*Data4cs Inc.: A consulting and AI solutions company that supports problem-solving and business growth across diverse industries through data science. Founded in 2005 with marketing analytics services, it now operates in multiple sectors including finance and life sciences. Key services include data analysis, AI system development, and DX (Digital Transformation) support. The company also focuses on training data scientists both internally and externally.
2025/08/08Announcement
We are pleased to announce the summary results of a Phase 2 clinical study of our ointment drug for the indication of verruca vulgaris being developed in collaboration with Iwaki Seiyaku CO.,LTD.
About Summary Results of Phase 2 Clinical Study on Verruca Vulgaris conducted by KinoPharma in collaboration with Iwaki Seiyaku as a Japanese Partner2025/07/22Announcement
KinoPharma is pleased to announce that as for our novel antiviral drug, we were allowed to grant the use patent for BPV infection by European Patent Office(EPO)
Patent Approved for Novel Antiviral Drug for Bovine Papillomavirus Infection in EuropeAbout KinoPharma
KinoPharma is a clinical stage biopharma to research and develop small-molecule drugs based on new concept in areas of high medical need, such as antiviral drugs, and provide them to patients around the world who are waiting for them as quickly as possible.
Business
Cervical cancer is caused by human papillomavirus (HPV) infection, which not only kills many women, but also causes the loss of the uterus through surgery. We are committed to developing drugs that can treat this disease before it develops.
Research and Development
We take a different approach to discovering and developing next generation antiviral drugs from previous antiviral strategies.
